106 related articles for article (PubMed ID: 24553204)
1. WHO plans for neglected diseases are wrong.
Moran M
Nature; 2014 Feb; 506(7488):267. PubMed ID: 24553204
[No Abstract] [Full Text] [Related]
2. [An alternative and innovative Research and Development model to ensure access to medicines - Neglected diseases, neglected populations, and biomedical innovation system].
Pécoul B
Med Sci (Paris); 2016 Dec; 32(12):1049-1050. PubMed ID: 28044961
[No Abstract] [Full Text] [Related]
3. WHO: Steering plans for neglected diseases.
Pécoul B; Balasegaram M
Nature; 2014 Mar; 507(7493):431. PubMed ID: 24670749
[No Abstract] [Full Text] [Related]
4. Funding: Donor drugs.
Willyard C
Nature; 2016 May; 533(7601):S43-5. PubMed ID: 27144609
[No Abstract] [Full Text] [Related]
5. Tropical disease: A neglected cause.
Laursen L
Nature; 2016 May; 533(7602):S68-9. PubMed ID: 27167396
[No Abstract] [Full Text] [Related]
6. Interdependencies among clinical research funders.
Hobbs FD
BMJ; 2014 Aug; 349():g4892. PubMed ID: 25125364
[No Abstract] [Full Text] [Related]
7. [Neglected tropical diseases: a New World Health Organization program].
Sergiev VP; Migliorini L; Litvinov SK; Chernikova EA
Med Parazitol (Mosk); 2014; (2):59-63. PubMed ID: 25296432
[No Abstract] [Full Text] [Related]
8. Current trends in and future potential of crowdfunding to finance R&D of treatments for neglected tropical diseases.
Benazzouz SM; Malkinson J; Tóth G
Drug Discov Today; 2021 Jul; 26(7):1563-1568. PubMed ID: 33640317
[TBL] [Abstract][Full Text] [Related]
9. [Industry, Academia and Government Partnership through the Global Health Innovative Technology Fund (GHIT)].
Hinoshita E
Yakugaku Zasshi; 2016; 136(2):237-42. PubMed ID: 26831799
[TBL] [Abstract][Full Text] [Related]
10. Privatized Pharmaceutical Innovation vs Access to Essential Medicines: A Global Framework for Equitable Sharing of Benefits.
Burci GL; Gostin LO
JAMA; 2017 Feb; 317(5):473-474. PubMed ID: 28170485
[No Abstract] [Full Text] [Related]
11. Resolving "worm wars": An extended comparison review of findings from key economics and epidemiological studies.
Majid MF; Kang SJ; Hotez PJ
PLoS Negl Trop Dis; 2019 Mar; 13(3):e0006940. PubMed ID: 30845181
[No Abstract] [Full Text] [Related]
12. Philanthropy, medical research, and the role of development.
Wheeler JL; Rum SA; Wright SM
Am J Med; 2014 Oct; 127(10):903-4. PubMed ID: 24858063
[No Abstract] [Full Text] [Related]
13. [Clinical research and pharmacy industry].
Grandi C
Rev Fac Cien Med Univ Nac Cordoba; 2013; 70(4):185-6. PubMed ID: 24650648
[No Abstract] [Full Text] [Related]
14. US incentive scheme for neglected diseases: a good idea gone wrong?
Doshi P
BMJ; 2014 Jul; 349():g4665. PubMed ID: 25099712
[No Abstract] [Full Text] [Related]
15. Disease research: Rare insights.
Ledford H
Nature; 2014 Jan; 505(7483):443-5. PubMed ID: 24436966
[No Abstract] [Full Text] [Related]
16. Hit and lead criteria in drug discovery for infectious diseases of the developing world.
Katsuno K; Burrows JN; Duncan K; Hooft van Huijsduijnen R; Kaneko T; Kita K; Mowbray CE; Schmatz D; Warner P; Slingsby BT
Nat Rev Drug Discov; 2015 Nov; 14(11):751-8. PubMed ID: 26435527
[TBL] [Abstract][Full Text] [Related]
17. Poverty-related and neglected diseases - an economic and epidemiological analysis of poverty relatedness and neglect in research and development.
von Philipsborn P; Steinbeis F; Bender ME; Regmi S; Tinnemann P
Glob Health Action; 2015; 8():25818. PubMed ID: 25623607
[TBL] [Abstract][Full Text] [Related]
18. Public health round-up.
Bull World Health Organ; 2019 Mar; 97(3):172-173. PubMed ID: 30992628
[No Abstract] [Full Text] [Related]
19. Funding innovation in neglected diseases.
Yamey G; Batson A; Kilmarx PH; Yotebieng M
BMJ; 2018 Mar; 360():k1182. PubMed ID: 29559440
[TBL] [Abstract][Full Text] [Related]
20. Busting the billion-dollar myth: how to slash the cost of drug development.
Maxmen A
Nature; 2016 Aug; 536(7617):388-90. PubMed ID: 27558048
[No Abstract] [Full Text] [Related]
[Next] [New Search]
